Ioversol clinical trials
Also written Optiray.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2009
How each study uses ioversol is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 30 Dec 1988 · OPTIRAY 350 · NDA 019710 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
3 studies that test it; most in 2009 (1)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2014 | 1 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 1
Washington University School of Medicine (1) · Guerbet (1) · GE Healthcare (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses ioversol is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Pediatric Risk of Hypothyroidism With Iodinated Contrast MediaWithdrawnPhase 4GE HealthcareNCT03631771Written as Ioversol
- Effects of Contrast Media on Subjects With Stable Reduced Renal Function Undergoing Contrast-Enhanced Computed TomographyTerminatedPhase 4GuerbetNCT00793182Written as Ioversol 320 mgI/mL
- Abdominal CT to Predict the Risk of Acute Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell TransplantationCompletedEarly Phase 1Washington University School of MedicineNCT02117115Written as Ioversol
Codes
What other systems call ioversol · ClinicalTrials.gg INT003364
- MeSH (NLM) C054871ioversolConfirmed NLM, Wikidata
- UNII (FDA) N3RIB7X24KIOVERSOLConfirmed FDA, NLM, Wikidata
- RxNorm 27792Confirmed FDA, Wikidata
- Wikidata Q6064187ioversolConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C65947IoversolOne source FDA
- DrugBank DB09134One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C054871 | ioversol | Confirmed NLM, Wikidata |
| UNII (FDA) | N3RIB7X24K | IOVERSOL | Confirmed FDA, NLM, Wikidata |
| RxNorm | 27792 | — | Confirmed FDA, Wikidata |
| Wikidata | Q6064187 | ioversol | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C65947 | Ioversol | One source FDA |
| DrugBank | DB09134 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.